Status: Recruiting
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI) treatment
Participants needed: 40
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shenzhen TargetRx Co., Ltd.Updated: Feb 21, 2025Locations: 1
Eligibility criteria
Willing to consent [+15]
Reception of TKI treatment or presence of unrecovered TKI treatment related non-... [+20]